It’s no secret that drugs don’t work equally well for everyone. Doug Cole, chairman and co-founder of Vesalius Therapeutics, saw these limitations while he was a practicing physician in the 1990s.

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that includes a preclinical small molecule initially targeting Parkinson’s disease.

Please provide your email address to receive an email when new articles are posted on . The VESALIUS-CV trial evaluated the impact of the PCSK9 inhibitor evolocumab on risk for major adverse ...

Success rates in drug research for common diseases is low, and one reason for that could be perspective. Science has approached each common disorder as a single disease affecting a large population of ...

After two years of developing its platform, Vesalius Therapeutics Inc. now has $75 million in its pocket from Flagship Pioneering to understand and treat the diseases that account for 90% of the world ...

Women's telehealth company Wisp announced a strategic partnership with Vesalius Longevity Labs, a company that provides regenerative medicine, to develop an exclusive range of peptide therapies aimed ...

Researchers at VCU Massey Comprehensive Cancer Center have developed a new computational tool called Vesalius, which could help clinicians understand the complex relationships between cancer cells and ...

Philadelphia’s College of Physicians is home to tens of thousands of books on medicine spanning centuries of health and science. This week, the group will bring out one of its most prized volumes, a ...

Vesalius Longevity Labs, the first soon-to-be publicly traded company dedicated exclusively to longevity science, today announced a landmark partnership with Wisp, the largest women’s telehealth ...